US4495851085 - Common Stock
IGM BIOSCIENCES INC
NASDAQ:IGMS (10/11/2024, 8:05:58 PM)
After market: 15 0 (0%)15
+1.11 (+7.99%)
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 216 full-time employees. The company went IPO on 2019-09-18. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
IGM BIOSCIENCES INC
325 E Middlefield Rd
Mountain View CALIFORNIA 94043
P: 16509657873
CEO: Fred Schwarzer
Employees: 204
Website: https://igmbio.com/
Wednesday's pre-market session: top gainers and losers
The company is making a complete shift out of oncology and into autoimmune diseases.
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Which stocks are moving after the closing bell on Monday?
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis...
Here you can normally see the latest stock twits on IGMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: